Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2025 · 10-Q
Revenue$167.20M$167.20M+7.8% vs Q3 2024 Net Income-$37.27M-$37.27MN/M vs Q3 2024 EPS Diluted-$0.33-$0.33N/M vs Q3 2024 Gross Profit$122,475,000+2.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$20,574,000+98.3% Free Cash Flowderived$14,919,000N/M Margins · derivedGross margin73.2%−3.9 pt vs Q3 2024
Operating margin-21.5%−0.9 pt vs Q3 2024
Net margin-22.3%−2.6 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end